117 related articles for article (PubMed ID: 38659481)
1. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based cancer immunotherapy for colorectal cancer.
Kajihara M; Takakura K; Kanai T; Ito Z; Saito K; Takami S; Shimodaira S; Okamoto M; Ohkusa T; Koido S
World J Gastroenterol; 2016 May; 22(17):4275-86. PubMed ID: 27158196
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review.
Guven DC; Kavgaci G; Erul E; Syed MP; Magge T; Saeed A; Yalcin S; Sahin IH
Oncologist; 2024 May; 29(5):e580-e600. PubMed ID: 38309719
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for esophageal cancer: Where are we now and where can we go.
Shoji Y; Koyanagi K; Kanamori K; Tajima K; Ogimi M; Ninomiya Y; Yamamoto M; Kazuno A; Nabeshima K; Nishi T; Mori M
World J Gastroenterol; 2024 May; 30(19):2496-2501. PubMed ID: 38817664
[TBL] [Abstract][Full Text] [Related]
6. Clinical Development of Immune Checkpoint Inhibitors.
Ito A; Kondo S; Tada K; Kitano S
Biomed Res Int; 2015; 2015():605478. PubMed ID: 26161407
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic impact of programmed death - 1 in the treatment of colorectal cancer.
Sangani PS; Yazdani S; Khalili-Tanha G; Ghorbani E; Al-Hayawi IS; Fiuji H; Khazaei M; Hassanian SM; Kiani M; Ghayour-Mobarhan M; Ferns GA; Nazari E; Avan A
Pathol Res Pract; 2024 May; 259():155345. PubMed ID: 38805760
[TBL] [Abstract][Full Text] [Related]
8. Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.
Assal A; Kaner J; Pendurti G; Zang X
Immunotherapy; 2015; 7(11):1169-86. PubMed ID: 26567614
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Colorectal Cancer - Finding the Achilles' Heel.
Park R; Saeed A
NEJM Evid; 2024 Jun; 3(6):EVIDra2300353. PubMed ID: 38804784
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy and immunology.
Wang L; Lynch C; Pitroda SP; Piffkó A; Yang K; Huser AK; Liang HL; Weichselbaum RR
J Exp Med; 2024 Jul; 221(7):. PubMed ID: 38771260
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic oncolysis by tigilanol tiglate.
Pol JG; Lizarralde-Guerrero M; Kroemer G
Oncoimmunology; 2024; 13(1):2360230. PubMed ID: 38812571
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in immunotherapy in cancer treatment.
Patel AA
Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):89-99. PubMed ID: 38814230
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors.
Wan Z; Huang J; Ou X; Lou S; Wan J; Shen Z
An Bras Dermatol; 2024; 99(3):425-432. PubMed ID: 38388337
[TBL] [Abstract][Full Text] [Related]
14. Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer.
Oliveres H; Cascante M; Maurel J
Curr Opin Chem Biol; 2023 Dec; 77():102401. PubMed ID: 37806262
[TBL] [Abstract][Full Text] [Related]
15. Advancements in combining targeted therapy and immunotherapy for colorectal cancer.
Singh M; Morris VK; Bandey IN; Hong DS; Kopetz S
Trends Cancer; 2024 May; ():. PubMed ID: 38821852
[TBL] [Abstract][Full Text] [Related]
16. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N; Li X; Zhang X; Xue S; Cao Y; Niedermann G; Lu Y; Xue J
Signal Transduct Target Ther; 2024 May; 9(1):126. PubMed ID: 38773064
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors in Esophageal Carcinoma: Assessment of Efficacy Predictors of Response in Clinical Trials.
Abushukair H; Abushukair A; Singh M; Saeed A
Surg Oncol Clin N Am; 2024 Jul; 33(3):583-593. PubMed ID: 38789200
[TBL] [Abstract][Full Text] [Related]
18. Updates on the Management of Colorectal Cancer in Older Adults.
O'Donnell CDJ; Hubbard J; Jin Z
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791899
[TBL] [Abstract][Full Text] [Related]
19. Targeting angiogenesis in gastrointestinal tumors: current challenges.
Nandikolla AG; Rajdev L
Transl Gastroenterol Hepatol; 2016; 1():67. PubMed ID: 28138633
[TBL] [Abstract][Full Text] [Related]
20. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer.
Licata L; Dieci MV; De Angelis C; Marchiò C; Miglietta F; Cortesi L; Fabi A; Schmid P; Cortes J; Pusztai L; Bianchini G; Curigliano G
Cancer Treat Rev; 2024 May; 128():102762. PubMed ID: 38776613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
